BioSpace News Archive

FDA

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.

July 20, 2023
·
7 min read
Biotech Bay

SFHP LEADS MEDI-CAL COVID-19 VACCINATION RATES FOR THREE STRAIGHT QUARTERS

For the third straight quarter, San Francisco Health Plan (SFHP) is ranked number one among managed care plans for Medi-Cal COVID-19 vaccination rates.

July 20, 2023
·
2 min read
US FDA Grants Orphan Drug Designation of SN Bioscience’s Nano Anti-Cancer Drug ‘SNB-101' for Small Cell Lung Cancer

SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on July 19 that the US FDA had granted an orphan drug designation for small cell lung cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development.

July 20, 2023
·
2 min read
Biotech Beach

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that it has executed financing to provide further working capital and support its ongoing business operations.

July 20, 2023
·
6 min read
Genetown

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, is pleased to announce that the company will present its clinical results in the form of Proffered Paper presentation at the 2023 European Society for Medical Oncology Congress.

July 20, 2023
·
2 min read